Nastech Pharmaceutical Company, Inc.

Jame Fine Chemicals, Inc.

Raja G Achari

Anthony P Sileno

Charanjit R Behl

Vincent D Romeo

Jorge C deMeireles

Vilas M Chopdekar

Sham N Redkar

Tianquing Liu

Shamim Ahmed

James R Schleck

Angelo Mellozzi

Ramneik Dua

The invention pertains to a method for preparing diphenhydramine tannate by reacting diphenhydramine free base at a temperature of about 75 to about 150&#xb0; C. with tannic acid neat or as an aqueous slurry containing up to about 20 wt. % water. The diphenhydramine free base may be obtained by reacting a commercially available diphenhydramine salt such as diphenhydramine maleate with a base such as aqueous sodium hydroxide. The resultant diphenhydramine tannate has extended release properties and is useful in pharmaceutical compositions as an antihistamine for human beings.

Hot melt method for preparing diphenhydramine tannate

The invention pertains to a method for preparing dexchlorpheniramine ('dexchlor') tannate by reacting dexchlorpheniramine free base at a temperature of about 75 to about 150&#xb0; C. with tannic acid neat or as an aqueous slurry containing up to about 20 wt. % water. The dexchlorpheniramine free base may be obtained by reacting a commercially available dexchlorpheniramine salt such as dexchlorpheniramine maleate with a base such as aqueous sodium hydroxide. The resultant dexchlor tannate has extended release properties and is useful in pharmaceutical compositions as an antihistamine for human beings.

Method for preparing dexchlor tannate

Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.

Nasal delivery of apomorphine

The present invention relates to a pharmaceutical formulation for intranasal administration comprising morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0. Such formulations provide enhanced absorption of morphine or pharmaceutically acceptable salts thereof. In one embodiment, the present invention provides a method for eliciting an analgesic or anesthetic response in a mammal which includes nasally administering a therapeutically effective amount of morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0.

Methods comprising intranasal morphine

Growing community of inventors

Millington, NJ, United States of America

Raja G Achari